secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001104659-24-059322
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance reports Q1 net loss $113M; Amtagvi launch strong with 100+ patients enrolled across 40+ ATCs
--------------------------------------------------------------------------------

- Net loss $113.0M ($0.42 per share) vs $107.4M ($0.50) YoY; revenue $0.7M from Proleukin sales.
- Cash, equivalents & investments $362.6M vs $346.3M at Dec 31, 2023; runway into H2 2025.
- More than 100 patients enrolled for Amtagvi since Feb 16 FDA approval; ~50 ATCs on track by end of May, 70+ by year-end.
- Manufacturing turnaround ~34 days; >75% of enrolled patients covered by private payers.
- Regulatory filings for lifileucel on track in EU (Q2 2024), UK/Canada (H2 2024), Australia (2025).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924059322/0001104659-24-059322-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924059322/tm2413980d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-059322

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer